Taking Advantage of the Selectivity of Histone Deacetylases and Phosphodiesterase Inhibitors to Design Better Therapeutic Strategies to Treat Alzheimer’s Disease
Mar Cuadrado‐Tejedor(Universidad de Navarra), Ana Garcı́a-Osta(Navarre Institute of Health Research)
Cited by 46
Related Papers
Phenylbutyrate Ameliorates Cognitive Deficit and Reduces Tau Pathology in an Alzheimer's Disease Mouse Model
|Neuropsychopharmacology|2009|413
Sildenafil restores cognitive function without affecting β-amyloid burden in a mouse model of Alzheimer's disease
|British Journal of Pharmacology|2011|210
Enhanced Expression of the Voltage-Dependent Anion Channel 1 (VDAC1) in Alzheimer's Disease Transgenic Mice: An Insight into the Pathogenic Effects of Amyloid-β
|Journal of Alzheimer s Disease|2011|137
A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer’s Disease Mice
|Neuropsychopharmacology|2016|104
MuSK Expressed in the Brain Mediates Cholinergic Responses, Synaptic Plasticity, and Memory Formation
|Journal of Neuroscience|2006|94